Regulatory Science «A Ferring perspective» Sukhwinder S. Jossan, PhD Associate Vice President, Global Regulatory Affairs

Size: px
Start display at page:

Download "Regulatory Science «A Ferring perspective» Sukhwinder S. Jossan, PhD Associate Vice President, Global Regulatory Affairs"

Transcription

1 Regulatory Science «A Ferring perspective» Sukhwinder S. Jossan, PhD Associate Vice President, Global Regulatory Affairs

2 Regulatory Science: Introduction Literature search in1985 did not find the phrase regulatory science In 2014 search for regulatory science resulted in 200,000 hits Insignificant role of science in decision process before 19th century Religious leaders and other authorities established laws and policy Science was insufficiently developed and intermingled with beliefs Advancement of industries resulted in need to regulate for instance manufacturing or air pollution 1

3 Regulatory Science: Introduction Regulation required relevant scientific information - regulatory science The term regulatory was first used by in 1970 Regulatory science described as the science used to develop regulations Institute for Regulatory Science was established in 1985 Regulatory science refers broadly to the scientific and technical foundations upon which regulations are based in various industries particularly those involving health or safety Regulatory science is increasingly recognized as an evolving science serving regulatory and other policy decision making 2

4 Regulatory Science and Regulatory Affairs Regulatory Science focuses on the scientific underpinnings and concerns Regulatory affairs and regulatory law refer to the administrative and legal aspects including implementation, compliance, or enforcement 3

5 Regulatory Science: Definition FDA Regulatory Science is the science of developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of all FDA-regulated products CORS Regulatory Science "The science of developing new tools, standards and approaches to evaluate the efficacy, safety, quality and performance of medical products in order to assess benefit-risk and facilitate a sound and transparent regulatory decision making Regulatory science a scientific discipline consisting of the development and application of scientific methods, tools, approaches, and other relevant processes derived from various scientific disciplines used to support regulatory and other policy objectives. An abbreviated definition regulatory science consists of the application of science to support policy notably regulatory objectives 4

6 Regulatory Science: Future FDA s Strategic Plan for Regulatory Science is designed to allow the Agency both to meet today s public and animal health needs and to be fully prepared for the challenges and opportunities of tomorrow to help harness revolutions in science that can be translated into products that help make and keep our nation both safe and healthy 5

7 Regulatory Science: Future The need for transparency in regulatory science by identifying assumptions, judgments, and related processes during the regulatory science process. Those involved in development of regulations, typically this group is employed by regulatory agencies Those who must comply with regulations, typically this group consists of employees or contractors of regulated community The scientific community who performs research and development in relevant areas 6

8 Dose finding and dose selection Workshop held in London in Dec 2014 Academia, Regulatory bodies and Industry participated Misconception: D-E-R and dose selection are solely at Company s risk Debate to update dose finding regulatory guidance FDA and EMA s experience phase 2 is often abbreviated The selection of dose is frequently empirical and rarely scientifically sound Poor dose selection may result in delayed rejection, changes in dose post approval Poor dose selection is one of the main causes for increasing cost of drug development 7

9 Dose finding and dose selection Conclusions Model-based dose finding methods are more efficient than pairwise comparisons approaches Longitudinal data analysis, time vs drug effect, a powerful tool Implementation of innovative approach requires support of senior research and development industry leaders Improved regulatory guidance from HA can drive engagement from senior leadership 8

10 Thorough QT study-early QT Assessment ICH, E14 requires most NCEs to be tested in a specifically designed TQT study Collaboration to design Phase 1 study to generate data to replace a thorough QT study Six marketed drugs with QTc effects were identified Randomized placebo-controlled study in 20 healthy subjects Two doses of each drug on separate, consecutive days Study designed in collaboration with the FDA 9

11 Thorough QT study-early QT Assessment Successful outcome to provide evidence supporting replacement of the TQT with ECG in standard early development studies for a new chemical entity The group fulfilled its goal of conducting a prospective study in early Phase1 with 5 known QTc positive drugs and one QTc negative drug On the bases of these results FDA has begun considering to grant waiver for TQT studies 10

12 Complex biological medicinal products 11

13 Regulatory Science: Introduction regulatory science is both interdisciplinary and multidisciplinary and relies upon a large number of basic and applied scientific disciplines Regulatory science is an emerging area of interest within pharmaceutical medicine as the shaping and implementation of legislation and guidelines 12

THE EXPERT PRECISION QT APPROACH

THE EXPERT PRECISION QT APPROACH WHITE PAPER THE EXPERT PRECISION QT APPROACH Driving earlier assessments of cardiac safety and supporting regulatory change Borje Darpo, MD, PhD February 2018 TABLE OF CONTENTS THE CARDIAC SAFETY TESTING

More information

The importance of regulatory science in a societal and industrial perspective Annual Conference CORS 24 November 2016

The importance of regulatory science in a societal and industrial perspective Annual Conference CORS 24 November 2016 The importance of regulatory science in a societal and industrial perspective Annual Conference CORS 24 November 2016 Marianne Kock, Head of Global Regulatory Affairs & Managing Director, Ferring Pharmaceuticals

More information

Setting the Scene - Industry. Regulatory Science. Merete Schmiegelow Senior Director, Regulatory Policy

Setting the Scene - Industry. Regulatory Science. Merete Schmiegelow Senior Director, Regulatory Policy CORS-Industry-241116 1 Regulatory Science Setting the Scene - Industry Merete Schmiegelow Senior Director, Regulatory Policy Honorary Industrial Ambassador in Regulatory Science at the University of Copenhagen

More information

Dose Selection in Drug Development and Regulation: Possible Future Direction. Richard Lalonde and Donald Stanski Pfizer and AstraZeneca

Dose Selection in Drug Development and Regulation: Possible Future Direction. Richard Lalonde and Donald Stanski Pfizer and AstraZeneca Dose Selection in Drug Development and Regulation: Possible Future Direction Richard Lalonde and Donald Stanski Pfizer and AstraZeneca Overview What is the problem and how did we get here Examples of the

More information

Introduction to clinical trials

Introduction to clinical trials Introduction to clinical trials Definition of a clinical trial A research activity that involves administration of a test treatment to some experimental unit in order to evaluate the treatment. Key words

More information

Celerion s Symposia Series: Bridging the Gap from Phase I to Proof-of-Concept. San Francisco, CA Tue 8 th, Apr 2014

Celerion s Symposia Series: Bridging the Gap from Phase I to Proof-of-Concept. San Francisco, CA Tue 8 th, Apr 2014 Celerion s Symposia Series: Bridging the Gap from Phase I to Proof-of-Concept San Francisco, CA Tue 8 th, Apr 2014 Mind the Gap: Elements of a Bridging Strategy J. Fred Pritchard, Ph.D. Vice President,

More information

Chin Koerner Executive Director US Regulatory and Development Policy

Chin Koerner Executive Director US Regulatory and Development Policy Chin Koerner Executive Director US Regulatory and Development Policy Novartis Pharmaceuticals Corporation 1700 Rockville Pike Suite 510 Rockville, MD 20852 Tel 301.468.5607 Fax 301.468.5614 Email: Chin.Koerner@novartis.com

More information

Agreed with W. Cornell Graduate Program and Tri-I

Agreed with W. Cornell Graduate Program and Tri-I Drug Development Course From Molecule to Prescription Weill Cornell Graduate School - Tri-Institutional Therapeutics Discovery Institute ABOUT THIS COURSE This course has been designed in collaboration

More information

Experience with Adaptive Dose-Ranging Studies in Early Clinical Development

Experience with Adaptive Dose-Ranging Studies in Early Clinical Development Experience with Adaptive Dose-Ranging Studies in Early Clinical Development Judith Quinlan MSc Vice President Adaptive Trials Cytel Inc. judith.quinlan@cytel.com Thanks to members of the PhRMA Adaptive

More information

Pediatric drug development - do we need a PIP so early in development? American versus European approach

Pediatric drug development - do we need a PIP so early in development? American versus European approach Pediatric drug development - do we need a PIP so early in development? American versus European approach Angelika Joos Executive Director, Global Regulatory Policy Merck Sharp & Dohme (Europe) Inc., Brussels

More information

International Transfers of Personal Data at sanofi-aventis R & D

International Transfers of Personal Data at sanofi-aventis R & D International Transfers of Personal Data at sanofi-aventis R & D Pierre-Yves Lastic, PhD Senior Director, Standards Management & Data Privacy Sanofi-aventis R&D CONFERENCE ON INTERNATIONAL TRANSFERS OF

More information

CAREER DEVELOPMENT FOR EXPERIENCED REGULATORY PROFESSIONALS

CAREER DEVELOPMENT FOR EXPERIENCED REGULATORY PROFESSIONALS CAREER DEVELOPMENT FOR EXPERIENCED REGULATORY PROFESSIONALS How TOPRA can support you as you drive your regulatory career forward ABOUT TOPRA TOPRA (The Organisation for Professionals in Regulatory Affairs)

More information

CDER Perspective: Good Clinical Practice

CDER Perspective: Good Clinical Practice CDER Perspective: Good Clinical Practice Sensible Guidelines Symposium, 25 May 2012 Ann Meeker-O Connell FDA, CDER, Office of Compliance Office of Scientific Investigations The views presented in this

More information

MAXIMIZING THE VALUE OF CLINICAL TRIALS DATA: A COLLABORATIVE FRAMEWORK FOR DATA STANDARDS GOVERNANCE FROM DATA DEFINITION TO KNOWLEDGE MANAGEMENT

MAXIMIZING THE VALUE OF CLINICAL TRIALS DATA: A COLLABORATIVE FRAMEWORK FOR DATA STANDARDS GOVERNANCE FROM DATA DEFINITION TO KNOWLEDGE MANAGEMENT MAXIMIZING THE VALUE OF CLINICAL TRIALS DATA: A COLLABORATIVE FRAMEWORK FOR DATA STANDARDS GOVERNANCE FROM DATA DEFINITION TO KNOWLEDGE MANAGEMENT PharmaSUG Single Day Event Using Standards, Even for Non-Standard

More information

May 23, :30 PM-5:00 PM - AUDITORIUM A250. May 9, :30 PM -5:00 PM - AUDITORIUM A-950 May 16, :30 PM-5:00 PM - AUDITORIUM A250

May 23, :30 PM-5:00 PM - AUDITORIUM A250. May 9, :30 PM -5:00 PM - AUDITORIUM A-950 May 16, :30 PM-5:00 PM - AUDITORIUM A250 DRUG DEVELOPMENT COURSE - FROM MOLECULE TO PRESCRIPTION WEILL CORNELL GRADUATE SCHOOL - TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE THURSDAYS FROM 3:00PM - 5:00PM AT 1300 YORK AVE, NEW YORK, N.Y.

More information

8. Clinical Trial Assessment Phase II

8. Clinical Trial Assessment Phase II 8. Clinical Trial Assessment Phase II Junko Sato, PhD Office of New Drug I, PMDA Disclaimer: The information within this presentation is based on the presenter s expertise and experience, and represents

More information

European Paediatric Formulation Initiative

European Paediatric Formulation Initiative European Paediatric Formulation Initiative Formulating better medicines for children Dr Catherine Tuleu Chair of EuPFI Reader, Department of Pharmaceutics & Director, Centre for Paediatric Pharmacy Research

More information

Process Capability: Practical Challenges to Implementation

Process Capability: Practical Challenges to Implementation Process Capability: Practical Challenges to Implementation [in pharmaceutical manufacturing] 33rd Quality & Productivity Research Conference Tempe, AZ June 16, 2016 Julia O Neill julia.oneill@tunnellconsulting.com

More information

FDA from a Former FDAer: Secrets and insights into regulatory review and drug development

FDA from a Former FDAer: Secrets and insights into regulatory review and drug development FDA from a Former FDAer: Secrets and insights into regulatory review and drug development Andrew E. Mulberg, MD, FAAP Vice-President, Global Regulatory Affairs; Former Division Deputy, DGIEP, U.S. FDA

More information

Introduction and Case Sharing of FDA CGMP Inspections

Introduction and Case Sharing of FDA CGMP Inspections Presentation title Date Introduction and Case Sharing of FDA CGMP Inspections Second Russian GMP Conference 2017 Andrew Chang, Ph.D Vice President, Quality and Regulatory Compliance Novo Nordisk A/S Presentation

More information

Introduction to clinical trials Magnus Kjaer

Introduction to clinical trials Magnus Kjaer Introduction to clinical trials 2016-01-20 Magnus Kjaer One Definition of Clinical Trial NIH 2014 A research study in which one or more human subjects are prospectively assigned to one or more interventions

More information

January Summary

January Summary The Academy of Medical Sciences and the Royal Academy of Engineering joint response to the Medicine and Healthcare products Regulatory Agency s public consultation on the revision of European legislation

More information

MODEL-BASED DRUG DEVELOPMENT: A FDA CRITICAL PATH OPPORTUNITY

MODEL-BASED DRUG DEVELOPMENT: A FDA CRITICAL PATH OPPORTUNITY MODEL-BASED DRUG DEVELOPMENT: A FDA CRITICAL PATH OPPORTUNITY Donald R. Stanski MD Scientific Advisor, Office of the Commissioner, FDA Professor of Anesthesia Stanford University, CA THE OPINIONS EXPRESSED

More information

Ethics Committees/IRBs Today: Challenges for Efficiency and Quality

Ethics Committees/IRBs Today: Challenges for Efficiency and Quality Marjorie A. Speers, Ph.D. President and CEO Ethics Committees/IRBs Today: Challenges for Efficiency and Quality Copyright 2013 AAHRPP All rights reserved Goal Clinical Research Globally Access to patients

More information

EMA - Early Access. PEARRL Annual Meeting 2017-Regulatory Science Symposium. University College Cork, Ireland

EMA - Early Access. PEARRL Annual Meeting 2017-Regulatory Science Symposium. University College Cork, Ireland EMA - Early Access PEARRL Annual Meeting 2017-Regulatory Science Symposium University College Cork, Ireland Presented by Evangelos Kotzagiorgis Scientific Administrator, Quality of Medicines Office Specialised

More information

Designing Safe and Efficient Phase I Studies to Expedite Clinical Development

Designing Safe and Efficient Phase I Studies to Expedite Clinical Development Designing Safe and Efficient Phase I Studies to Expedite Clinical Development Mario Tanguay, B.Pharm, Ph.D. Vice President, Scientific & Regulatory Affairs, Anapharm Guest Professor, Faculty of Pharmacy,

More information

POLICY FOR RESEARCH INVOLVING DRUGS, BIOLOGICS OR DEVICES 6/1/2011

POLICY FOR RESEARCH INVOLVING DRUGS, BIOLOGICS OR DEVICES 6/1/2011 DUKE UNIVERSITY HEALTH SYSTEM Human Research Protection Program POLICY FOR RESEARCH INVOLVING DRUGS, BIOLOGICS OR DEVICES 6/1/2011 Research investigating or evaluating drugs, biologics or devices must

More information

Governance Code. Affinity Water Limited. March 2015

Governance Code. Affinity Water Limited. March 2015 Governance Code Affinity Water Limited March 2015 CONTENTS A INTRODUCTION... 3 B. BOARD LEADERSHIP... 3 C. BOARD BALANCE... 4 D BOARD COMMITTEES... 5 E BOARD EFFECTIVENESS... 5 F. FOCUSING ON OUR REGULATED

More information

The Future of Pharmaceutical Quality

The Future of Pharmaceutical Quality The Future of Pharmaceutical Quality First SQA/BIRS Center Meeting Purdue University Polytechnic Institute Louis W. Yu, Ph.D. Chief Quality Officer Unique Challenges of the Pharmaceutical Industry a. The

More information

Clinical Research: A Multifaceted Discipline

Clinical Research: A Multifaceted Discipline Clinical Research: A Multifaceted Discipline Anuradha Kulkarni a, Arun Bhatt b* a Senior Associate - Medical & Regulatory Affairs, Clininvent Research Pvt Ltd, A-302, Everest Chambers, Marol Naka, Andheri

More information

CDER Perspective: Challenges in Clinical Trials and the Path Forward

CDER Perspective: Challenges in Clinical Trials and the Path Forward CDER Perspective: Challenges in Clinical Trials and the Path Forward Pharmaceutical Compliance Congress and Best Practices Forum November 3, 2011 Ann Meeker O Connell, MS, CCEP Associate Director (Acting),

More information

COMPLIANCE MANAGEMENT FRAMEWORK FOR VICTORIA UNIVERSITY

COMPLIANCE MANAGEMENT FRAMEWORK FOR VICTORIA UNIVERSITY COMPLIANCE MANAGEMENT FRAMEWORK FOR VICTORIA UNIVERSITY July 2018 Prepared by: Policy Services (Compliance) Portfolio of the Vice-President (Planning) and Registrar Contents 1. BACKGROUND... 2 2. COMMITMENT

More information

Multiregional Regulatory Considerations in Pediatric Drug Development

Multiregional Regulatory Considerations in Pediatric Drug Development Multiregional Regulatory Considerations in Pediatric Drug Development Lynne Yao, M.D. Director Division of Pediatric and Maternal Health Office of New Drugs Center for Drug Evaluation and Research U.S.

More information

OREGON HEALTH AUTHORITY DRUG USE REVIEW/PHARMACY AND THERAPEUTICS COMMITTEE. OPERATING PROCEDURES Updated: March 2018

OREGON HEALTH AUTHORITY DRUG USE REVIEW/PHARMACY AND THERAPEUTICS COMMITTEE. OPERATING PROCEDURES Updated: March 2018 OREGON HEALTH AUTHORITY DRUG USE REVIEW/PHARMACY AND THERAPEUTICS COMMITTEE OPERATING PROCEDURES Updated: March 2018 MISSION: To encourage safe, effective, and innovative drug policies that promote high

More information

Statisticians in the Pharmaceutical Industry: The 21 st Century

Statisticians in the Pharmaceutical Industry: The 21 st Century Statisticians in the Pharmaceutical Industry: The 21 st Century Christy Chuang-Stein, Pfizer Ray Bain, Merck Cassie Burton, Novartis Cyrus Hoseyni, Wyeth Frank Rockhold, GlaxoSmithKline Stephen Ruberg,

More information

A Framework for Audit Quality

A Framework for Audit Quality Ernst & Young Global Limited Becket House 1 Lambeth Palace Road London SE1 7EU Tel: +44 [0]20 7980 0000 Fax: +44 [0]20 7980 0275 www.ey.com Mr. James Gunn Technical Director International Auditing and

More information

GAME CHANGING INNOVATION FOR CLINICAL DEVELOPMENT LEADERS

GAME CHANGING INNOVATION FOR CLINICAL DEVELOPMENT LEADERS GAME CHANGING INNOVATION FOR CLINICAL DEVELOPMENT LEADERS How might the pharmaceutical industry tackle the weighty issues of affordability and sustainability in the context of spiralling healthcare costs?

More information

March 2, Dear Chairman Upton, Ranking Member Pallone, and Representative DeGette:

March 2, Dear Chairman Upton, Ranking Member Pallone, and Representative DeGette: March 2, 2015 The Honorable Fred Upton Chairman Energy and Commerce Committee House of Representatives Washington, DC 20515 The Honorable Frank Pallone Ranking Member Energy and Commerce Committee House

More information

Amarex Clinical Research Washington DC metro area A Product Development Services Company. From Lab to Market Approval

Amarex Clinical Research Washington DC metro area A Product Development Services Company. From Lab to Market Approval Amarex Clinical Research Washington DC metro area A Product Development Services Company Regulatory Strategy From Lab to Market Approval Strategy Implementation Pre-Clinical Assays Global Clinical Trials

More information

A Generic Industry Perspective on Establishing Impurity Limits And a Corresponding Control Strategy

A Generic Industry Perspective on Establishing Impurity Limits And a Corresponding Control Strategy A Generic Industry Perspective on Establishing Impurity Limits And a Corresponding Control Strategy Nicholas Cappuccino, PhD Vice-President, Head of Quality and Scientific Affairs Dr. Reddy s Laboratories,

More information

Exploring Good Clinical Practice guidance in clinical trials meeting summary

Exploring Good Clinical Practice guidance in clinical trials meeting summary Exploring Good Clinical Practice guidance in clinical trials meeting summary Summary The ICH Good Clinical Practice (GCP) guidelines are currently being revised, providing an opportunity to review the

More information

Eisuke Hida & Yuki Ando Biostatistics group Pharmaceuticals and Medical Devices Agency

Eisuke Hida & Yuki Ando Biostatistics group Pharmaceuticals and Medical Devices Agency Eisuke Hida & Yuki Ando Biostatistics group Pharmaceuticals and Medical Devices Agency This is not an official PMDA guidance or policy statement. No official support or endorsement by the PMDA is intended

More information

From Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager

From Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager From Discovery to Development of new Drugs. and pitfalls along the way by Kim Dekermendjian, PhD in Medicine BD & Key Account manager The roots of Drug Discovery Before 20 th century the term didn't exists,

More information

September 12, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852

September 12, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 September 12, 2013 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: : Draft Guidance for Industry on Pediatric Study Plans: Content

More information

Certification in Pharmaceutical Medicine and Clinical Research The vision of regulators

Certification in Pharmaceutical Medicine and Clinical Research The vision of regulators Certification in Pharmaceutical Medicine and Clinical Research The vision of regulators Presented by Sergio Bonini Professor of Medicine, Second University of Naples Expert-on-Secondment, European Medicine

More information

Best practice in dose finding studies. Rudolf Koehne-Volland Head of Biostatistics & CEO Metronomia Clinical Research GmbH

Best practice in dose finding studies. Rudolf Koehne-Volland Head of Biostatistics & CEO Metronomia Clinical Research GmbH Best practice in dose finding studies Rudolf Koehne-Volland Head of Biostatistics & CEO Metronomia Clinical Research GmbH Best practice s in dose 13-Oct-2016 finding 2 Best practice in dose finding studies

More information

We appreciate the opportunity to submit these comments for your consideration.

We appreciate the opportunity to submit these comments for your consideration. February 28, 2018 European Medicines Agency 30 Churchill Place Canary Wharf London E14 5EU United Kingdom via email to rp-stats-qa@ema.europa.eu Dear Sir or Madam: The International Society for Pharmaceutical

More information

Corporate Social Responsibility (CSR) Statutory Report Innovating antibodies, improving lives

Corporate Social Responsibility (CSR) Statutory Report Innovating antibodies, improving lives Corporate Social Responsibility (CSR) Statutory Report 2012 Innovating antibodies, improving lives Statutory report on CSR for the financial year 2012 cf. Section 99a of the Danish Financial Statements

More information

Introductions and Perspectives on International Harmonization

Introductions and Perspectives on International Harmonization Introductions and Perspectives on International Harmonization FDA/PQRI Conference on Evolving Product Quality September 17 th 2014 Mark Rosolowsky, PhD Vice President Global Regulatory Sciences CMC Bristol-Myers

More information

Utility of preclinical PKPD modeling in QT safety testing

Utility of preclinical PKPD modeling in QT safety testing Utility of preclinical PKPD modeling in QT safety testing Sandra Visser & Piet van der Graaf EMA/EFPIA M&S Workshop on the role and scope of modelling and simulation in drug development BOS1, London 1

More information

Advancing Regulatory Science for Medical Countermeasures Development: An Institute of Medicine Workshop

Advancing Regulatory Science for Medical Countermeasures Development: An Institute of Medicine Workshop Institute of Medicine Workshop Venable Conference Center 29 Mar 2011 Advancing Regulatory Science for Medical Countermeasures Development: An Institute of Medicine Workshop Stephen J. Ruberg, PhD Distinguished

More information

Re: Public Consultation Paper on the Regulation of Advanced Therapy Medicinal Products

Re: Public Consultation Paper on the Regulation of Advanced Therapy Medicinal Products ISCT HEAD OFFICE Suite 201 375 West 5 th Avenue Vancouver, BC Canada V5Y 1J6 Tel: 604-874-4366 Fax: 604-874-4378 isct@celltherapysociety.org www.celltherapysociety.org March 30, 2013 European Commission,

More information

Regulatory Perspective

Regulatory Perspective Regulatory Perspective Presented by Dr Maria Isaac MASc, MD, PhD, Pharmaceutical Medicine Physician, Psychiatrist Senior Scientific Officer An agency of the European Union Disclaimer The views expressed

More information

Draft agreed by Scientific Advice Working Party 5 September Adopted by CHMP for release for consultation 19 September

Draft agreed by Scientific Advice Working Party 5 September Adopted by CHMP for release for consultation 19 September 23 January 2014 EMA/CHMP/SAWP/757052/2013 Committee for Medicinal Products for Human Use (CHMP) Qualification Opinion of MCP-Mod as an efficient statistical methodology for model-based design and analysis

More information

INTERAGENCY GUIDANCE ON THE ADVANCED MEASUREMENT APPROACHES FOR OPERATIONAL RISK

INTERAGENCY GUIDANCE ON THE ADVANCED MEASUREMENT APPROACHES FOR OPERATIONAL RISK INTERAGENCY GUIDANCE ON THE ADVANCED MEASUREMENT APPROACHES FOR OPERATIONAL RISK Robert Rell February 29, 2012 Disclaimer: The views expressed do not necessarily reflect the views of the Federal Reserve

More information

7/20/2016. Disclaimer

7/20/2016. Disclaimer Disclaimer Organizations may not re-use material presented at this AMCP webinar for commercial purposes without the written consent of the presenter, the person or organization holding copyright to the

More information

Visions on the role of Statisticians in the Pharmaceutical Industry. Merete Jørgensen President EFSPI VP Biostatistics, Novo Nordisk A/S

Visions on the role of Statisticians in the Pharmaceutical Industry. Merete Jørgensen President EFSPI VP Biostatistics, Novo Nordisk A/S Visions on the role of Statisticians in the Pharmaceutical Industry Merete Jørgensen President EFSPI VP Biostatistics, Novo Nordisk A/S Overview of presentation Vision & Mission A Historical view New Statistical

More information

VETERINARY DRUGS DIRECTORATE HEALTH PRODUCTS AND FOOD BRANCH HEALTH CANADA STRATEGIC PLAN

VETERINARY DRUGS DIRECTORATE HEALTH PRODUCTS AND FOOD BRANCH HEALTH CANADA STRATEGIC PLAN VETERINARY DRUGS DIRECTORATE HEALTH PRODUCTS AND FOOD BRANCH HEALTH CANADA STRATEGIC PLAN APRIL 2004 - MARCH 2007 TABLE OF CONTENTS INTRODUCTION... Page 2 of 12 ORGANIZATIONAL PROFILE AND HISTORY... Page

More information

How we set specifications for impurities (including Genotoxic impurities) 24 May 2017 Elisabeth Kovacs, Apotex CSO Chemistry and Analytical Sci.

How we set specifications for impurities (including Genotoxic impurities) 24 May 2017 Elisabeth Kovacs, Apotex CSO Chemistry and Analytical Sci. 2017 AAM CMC Workshop How we set specifications for impurities (including Genotoxic impurities) 24 May 2017 Elisabeth Kovacs, Apotex CSO Chemistry and Analytical Sci. The information within this presentation

More information

Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of the Paediatric Committee (PDCO)

Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of the Paediatric Committee (PDCO) Last revision: 16 September 2010 EMA/537415/2008 Human Medicines Development and Evaluation Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of

More information

Update on Current FDA Policies and Priorities

Update on Current FDA Policies and Priorities Update on Current FDA Policies and Priorities Vernessa Pollard MassMEDIC FDA Update December 12, 2017 Boston Brussels Chicago Dallas Düsseldorf Frankfurt Houston London Los Angeles Miami Milan Munich New

More information

Quality Culture A Regulatory Perspective Regulatory Compliance Associates Inc. All Rights Reserved

Quality Culture A Regulatory Perspective Regulatory Compliance Associates Inc. All Rights Reserved Quality Culture A Regulatory Perspective 8/15/2016 Quality Culture- The What Quality culture starts with leadership that understands that human behavior and motivations are critical to meeting ongoing

More information

New challenges on regulation of biotechnological products in peru

New challenges on regulation of biotechnological products in peru New challenges on regulation of biotechnological products in peru Hans Vásquez, MD, MPH Senior Clinical Reviewer Team of Biological Product General Directorate of Drugs and Medical Device Ministry of Health

More information

inventivhealthclinical.com The Goal: Reducing Uncertainty A Word on RBM

inventivhealthclinical.com The Goal: Reducing Uncertainty A Word on RBM Seeing Around Corners: Risk Assessment Is the Foundation of Risk-Based Monitoring By: Jeff Fetterman, President ParagonRX, an inventiv Health Company, Michael Macri, Director, Strategic Services, inventiv

More information

1201 Maryland Avenue SW, Suite 900, Washington, DC ,

1201 Maryland Avenue SW, Suite 900, Washington, DC , 1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org June 6, 2008 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville, MD

More information

Academia to Industry and Back

Academia to Industry and Back Academia to Industry and Back TRENT WATKINS, PH.D. ASSISTANT PROF., DEPT. OF NEUROSURGERY BAYLOR COLLEGE OF MEDICINE My winding career path Stanford: Ph.D. in Neuroscience Genentech: An academic research

More information

My Experiences as an FDA Statistician

My Experiences as an FDA Statistician My Experiences as an FDA Statistician Yeh-Fong Chen, Ph.D. FDA/CDER/OB/DB3 CBA 2016-2017 Workshop series-3 Dec. 18, 2016 Disclaimer This presentation reflects the views of the author and should not be

More information

STRATEGIC PLAN OF THE STATE INSTITUTE FOR DRUG CONTROL FOR Public Section

STRATEGIC PLAN OF THE STATE INSTITUTE FOR DRUG CONTROL FOR Public Section STRATEGIC PLAN OF THE STATE INSTITUTE FOR DRUG CONTROL FOR 2016-2020 Public Section 1 1. FOREWORD The document SÚKL Strategic Plan for 2016-2020 (hereinafter referred to as the Strategy ) summarises the

More information

Risk-Based Monitoring: How Can It Be Implemented For More Effective Study Oversight

Risk-Based Monitoring: How Can It Be Implemented For More Effective Study Oversight Risk-Based Monitoring: How Can It Be Implemented For More Effective Study Oversight Lisa Marie Saldanha Senior Director & Head of Operations Real World Insights Asia Singapore Research & Ethics Conference

More information

From Bench To Clinic : a personal journey Career Research Advancement Focused Training

From Bench To Clinic : a personal journey Career Research Advancement Focused Training From Bench To Clinic : a personal journey Career Research Advancement Focused Training February 13, 2018 Irina Tcherepanova Ph.D. Vice President of Translational Medicine Argos Therapeutics Inc. FDA view

More information

Introduction to Drug Design and Discovery

Introduction to Drug Design and Discovery Introduction to Drug Design and Discovery Course: Drug Design Course code: 0510412 Dr. Balakumar Chandrasekaran Dr. Bilal Al-Jaidi Assistant Professors, Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy,

More information

Safety Monitoring and Evaluation in Late Phase Clinical Development: An Application in OA Pain

Safety Monitoring and Evaluation in Late Phase Clinical Development: An Application in OA Pain Safety Monitoring and Evaluation in Late Phase Clinical Development: An Application in OA Pain José Pinheiro, Janssen R&D Joint work with Camille Orman, Steven Wang, and Elena Polverejan Janssen R&D Trends

More information

Re: Docket No. 2006D-0347, Federal Register: July 26, 2007 (Volume 72, Pages )

Re: Docket No. 2006D-0347, Federal Register: July 26, 2007 (Volume 72, Pages ) 1201 Maryland Avenue SW, Ste. 900 Washington, DC 20024 August 27, 2007 BY ELECTRONIC DELIVERY Division of Dockets Management (HFA-305) Food and Drug Administration 56350 Fishers Lane Room 1061 Rockville,

More information

What s New in GCP? FDA Clarifies, Expands Safety Reporting Guidance

What s New in GCP? FDA Clarifies, Expands Safety Reporting Guidance Vol. 9, No. 2, February 2013 Happy Trials to You What s New in GCP? FDA Clarifies, Expands Safety Reporting Guidance Reprinted from the Guide to Good Clinical Practice with permission of Thompson Publishing

More information

Challenges in Getting Global Approvals for Post-approval Changes

Challenges in Getting Global Approvals for Post-approval Changes Slide no 1 Supply Flexibility Program, ROFE 2009 Challenges in Getting Global Approvals for Post-approval Changes FDA/PQRI Conference on Evolving Product Quality September 17, 2014 Andrew Chang, Ph.D.

More information

Current Status and Perspectives of Placebo-controlled Studies

Current Status and Perspectives of Placebo-controlled Studies Provisional Translation (as of June 1, 2016) March 9, 2016 Current Status and Perspectives of Placebo-controlled Studies Subcommittee on Placebo-controlled Studies Kazuhiko Yamamoto, Chairperson Yoshihiro

More information

29 August Dear Sir/Madam:

29 August Dear Sir/Madam: 29 August 2016 Directorate General for Health and Food Safety DG SANTE Unit B4 "Medical products Quality, Safety and Innovation" European Commission F101 08/058 B-1049 Brussels RE: Public consultation

More information

PPTA Regulatory Workshop June 13, 2016

PPTA Regulatory Workshop June 13, 2016 PPTA Regulatory Workshop June 13, 2016 W. BRYAN SILVEY W. Bryan Silvey is the Senior Director, Global Regulatory Affairs/CMC for Baxalta US Inc. He is located at Baxalta s Westlake Village California regional

More information

BOTSWANA ACCOUNTANCY OVERSIGHT AUTHORITY (BAOA)

BOTSWANA ACCOUNTANCY OVERSIGHT AUTHORITY (BAOA) BOTSWANA ACCOUNTANCY OVERSIGHT AUTHORITY (BAOA) BOARD CHARTER BOTSWANA ACCOUNTANCY OVERSIGHT AUTHORITY BOARD CHARTER 1 TABLE OF CONTENTS CONTENTS PAGE 1. OVERVIEW 3 2. PURPOSE 3 3. COMPOSITION 3 4. INDUCTION

More information

Novel multiple testing procedures for structured study objectives and families of hypotheses a case study

Novel multiple testing procedures for structured study objectives and families of hypotheses a case study Novel multiple testing procedures for structured study objectives and families of hypotheses a case study Guenther Mueller-Velten Novartis Pharma AG EMA Workshop on Multiplicity Issues in Clinical Trials

More information

Continuous Manufacturing PMDA s Perspective

Continuous Manufacturing PMDA s Perspective Continuous Manufacturing PMDA s Perspective Yoshihiro Matsuda, Ph.D. Senior Scientist (for Quality) Pharmaceuticals and Medical Devices Agency (PMDA) Sep 27, 2016 ISCMP 1 A Background ICH(1) One of the

More information

Road map for the PMDA International Vision April 2013 Pharmaceuticals and Medical Devices Agency, Japan 1

Road map for the PMDA International Vision April 2013 Pharmaceuticals and Medical Devices Agency, Japan 1 Road map for the PMDA International Vision April 2013 Pharmaceuticals and Medical Devices Agency, Japan 1 1. Introduction The Pharmaceuticals and Medical Devices Agency (PMDA), a Japanese Incorporated

More information

Regulatory Pathways. Devices vs. Drugs Are there roles for registries? John Laschinger, MD CDRH/ODE/DCD/SHDB

Regulatory Pathways. Devices vs. Drugs Are there roles for registries? John Laschinger, MD CDRH/ODE/DCD/SHDB Regulatory Pathways Devices vs. Drugs Are there roles for registries? John Laschinger, MD CDRH/ODE/DCD/SHDB johnlaschinger@fda.hhs.gov 1 Disclosures and Disclaimer John C. Laschinger, M.D. I am a full

More information

Global Regulatory Director, Personalized Healthcare

Global Regulatory Director, Personalized Healthcare Date: 11/21/18 Global Regulatory Director, Personalized Healthcare Job ID: 201811-127364 Job Function Research Location United States of America - California South San Francisco Schedule Full time Job

More information

Regulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ

Regulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives

More information

Information Technology Strategy: Three Misconceptions

Information Technology Strategy: Three Misconceptions Information Technology Strategy: Three Misconceptions John P. Glaser, PhD A B S T R A C T The core intent in developing an IT strategy is to ensure that there is a strong and clear relationship between

More information

Regulatory Considerations and Trends Europe and the U.S.

Regulatory Considerations and Trends Europe and the U.S. Regulatory Considerations and Trends Europe and the U.S. Professor Kjell Strandberg MD PhD Chairman NDA Advisory Board, NDA Regulatory Science Ltd UK Former CPMP Member and Director General Medical Products

More information

The Future of Drug Safety

The Future of Drug Safety The Future of Drug Safety IOM Committee on the Assessment of the US Drug Safety System R. Alta Charo Warren P. Knowles Professor of Law & Bioethics University of Wisconsin Charge to the Committee Examine

More information

Re: Docket No. FDA-2015-D-4562: Draft Guidance Safety Assessment for IND Safety Reporting

Re: Docket No. FDA-2015-D-4562: Draft Guidance Safety Assessment for IND Safety Reporting February 16, 2016 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA-2015-D-4562: Draft Guidance Safety Assessment for IND

More information

The 21st Century Cures Act

The 21st Century Cures Act The 21st Century Cures Act Published: Dec 14, 2016 By: David S. Guzick, M.D., Ph.D.Category: UF Health In recent weeks, the 21st Century Cures Act was passed overwhelmingly by both chambers of the U.S.

More information

Coordination and Support Action: Enabling platform on medicines adaptive pathways to patients

Coordination and Support Action: Enabling platform on medicines adaptive pathways to patients Coordination and Support Action: Enabling platform on medicines adaptive pathways to patients Solange Rohou (AZ) & Luk Maes (BMS) 17.12.2014 IMI webinar Content Background information CSA project proposal

More information

Your complimentary Clinica Medtech Intelligence content

Your complimentary Clinica Medtech Intelligence content Your complimentary Clinica Medtech Intelligence content Clinica provides you with up to the minute coverage and opinion on company, product, market and regulatory developments as well as market size, growth

More information

PMDA Town Hall. Tatsuya KONDO, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA)

PMDA Town Hall. Tatsuya KONDO, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA) PMDA Town Hall - New Regulation in Japan and Future Direction of PMDA Tatsuya KONDO, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed

More information

Regulatory Analysis at the Intersection of Science and Policy

Regulatory Analysis at the Intersection of Science and Policy Regulatory Analysis at the Intersection of Science and Policy Prepared by: Lisa A. Robinson Harvard T.H. Chan School of Public Health Center for Risk Analysis and Center for Health Decision Science Prepared

More information

Advancing Regulatory Science at the US Food and Drug Administration

Advancing Regulatory Science at the US Food and Drug Administration Advancing Regulatory Science at the US Food and Drug Administration US Food and Drug Administration EPAA Annual Conference Brussels 9 November 2011 1 Suzanne C. Fitzpatrick, PhD, DABT Senior Science Advisor

More information

Scientific Advisory Groups (SAG)

Scientific Advisory Groups (SAG) Scientific Advisory Groups (SAG) Experience and impact of patient involvement Presented by: Francesco Pignatti Human Medicines Evaluation Division, EMA Training session for patients and consumers involved

More information

Inaugural Fraunhofer Delaware Technology Summit

Inaugural Fraunhofer Delaware Technology Summit Inaugural Fraunhofer Delaware Technology Summit Energy and Life Sciences Solu

More information

DRAFT December 21, 2017

DRAFT December 21, 2017 FINANCIAL SERVICES JOB FAMILY FINANCIAL SERVICES MANAGEMENT JOB FAMILY CONCEPT: The Financial Services job family is responsible for all aspects of accounting, budgeting, and financial activities related

More information

Unified understanding of MS disease is required for drug development. National Multiple Sclerosis Society, 733 Third Avenue, New York, NY USA 2

Unified understanding of MS disease is required for drug development. National Multiple Sclerosis Society, 733 Third Avenue, New York, NY USA 2 COMMENT Unified understanding of MS disease is required for drug development Timothy Coetzee 1 and Alan J Thompson 2 1 National Multiple Sclerosis Society, 733 Third Avenue, New York, NY 10017 USA 2 Faculty

More information

Strategies for Sustainability: corporate governance

Strategies for Sustainability: corporate governance Strategies for Sustainability: corporate governance ZAHID QURESHI Senior Vice-President Development, International Cooperative and Mutual Insurance Federation (ICMIF) United Kingdom A microinsurance operation

More information